Kashish Goel

@djc795 @jtsaxon @JACCJournals @HamidNadira @Columbia @MayoClinic @PierreEliasMD @crfheart Incredible study!! Looking forward to the AI-ECG and how it can help diagnose valvular heart disease early

@jtsaxon @JACCJournals @HamidNadira Stay tuned for the next chapter-- PREVUE-AI, where we collaborated with experts at @Columbia and @MayoClinic to explore the use of AI-ECG algorithms to screen for structural heart disease in the community setting. @PierreEliasMD @crfheart

This week, a team of researchers quietly published in @JACCJournals one of the most profound studies of valvular heart disease in recent memory. The PREVUE-VALVE study used a decentralized, in-home echocardiography model to estimate the prevalence of valvular heart disease among U.S. adults aged 65–85. Importantly, this was not a clinic-based echo cohort; participants were recruited nationally and underwent comprehensive transthoracic echo in their homes, with studies interpreted by a core lab. That intentional design choice is critical: PREVUE-VALVE is a true prevalence study, accurately representing the true burden of valve disease in the U.S. population. The findings are striking: 8.2% of older Americans have moderate or greater valvular heart disease, and 18.4% have “clinically significant” disease when mild-to-moderate regurgitation is included. TR was the most common lesion, followed by AS, MR, AR, and MS. The burden rises sharply with age, reaching nearly 15% among adults aged 80–85. Extrapolated nationally, this means approximately 4.7 million Americans aged 65–85 currently have moderate or greater VHD, projected to increase to 6.5 million by 2060. Using the broader clinically significant definition, the number is already over 10 million and projected to approach 15 million. For structural heart programs, health systems, and policymakers, the message is clear: the valve disease burden is large, growing, and will require thoughtful planning around screening, access, and treatment capacity. Congratulations to @djc795, Michael 'Mickey' Brener MD MS, and all co-authors for a stunning glimpse into the present and future of valve disease! jacc.org/doi/epdf/10.10…

Presenting our age-stratified analysis from the EARLY TAVR trial showing that age did not affect impact of early intervention in asymptomatic severe AS!

Very important for valve ICs to join+participate in this ! Appreciate @SCAI efforts. Wish @ACCinTouch would do the same @PaulMahoneyMD @PaulTeirstein @kashishgoelmd @sameergafoor @AGoldsweig @SachinGoelMD @SuzanneJBaron

@aelsab Great!! Congratulations

Happy to share the new AHA Science Advisory on percutaneous mechanical aspiration in right-sided infective endocarditis. This document is intended to provide a balanced perspective on the growing interest in PMA, while outlining a structured approach to its contemporary use, recognizing that its optimal role remains to be defined and that prospective studies are still needed. Thank you to the writing group and AHA for this collaborative effort. @LBaddour1 @sanjum @drandrewsharp @SEH_MD @rajivxgulati @yadersandoval @HamidNadira @MayoClinicCV @kashishgoelmd @PradeepYadavMD @MayraGuerreroMD @mirvatalasnag @g_giustinoMD @PrajReddyMD @Grace_Lin_MD

Should professional societies like @SCAI get opinion from its members on critical matters? Yes- as it represents it members and decisions affect them. No - a small indoor committee knows the best! Please retweet to get some reasonable responses @ACCinTouch @kashishgoelmd @KHERA_MD @SVRaoMD @djc795 @SachinGoelMD @PaulMahoneyMD

Our first J-Valve case as part of the JOURNEY Trial for native aortic regurgitation is officially in the books. This represents an important step forward in expanding transcatheter options for AR for our region and beyond. Just as important as the technology is the team behind it. From advanced imaging to anesthesia to intervention, this was a true multidisciplinary effort—executed with the precision, coordination, and innovation that define Vanderbilt’s structural heart program. Proud of the team, and excited for what’s ahead as we continue to push the field forward.

@aelsab @MayoClinicCV @DrArgyle @kalazizimd @benhibbertMDPhD Looking forward to this discussion

Single vs double operator TAVR? TAVR suitability in the young? Please join the debate and discussions today #ACC26 cattendee.abstractsonline.com/meeting/21230/…

@adrianocaixeta Thank you

Great job by @kashishgoelmd and colleagues performing 3 Evoque TTVR in one day. Thank you for sharing!

Big day in the VUMC cath lab!! Today, we successfully performed 3 Evoque TTVR procedures — all using intracardiac echo (ICE) only and under MAC sedation. No TEE. No general anesthesia. Streamlined, efficient, and patient-centered. This is more than just procedural success — it’s a shift in how we think about TTVR: · Less invasive · Faster recovery · Expanded access for higher-risk patients A true game changer in structural heart interventions. Grateful to be pushing the field forward and building on the pioneering work of my friend Pradeep Yadav. The future of TTVR is here — and it’s simpler, smarter, and safer.

The Trisol #TTVR device is safe and effective in treating patients with tricuspid regurgitation and improves clinical outcomes at 12 months post-procedure, early feasibility study (EFS) results show. Read more from #CRT2026 on #CRTonline. ow.ly/3r3S50Yt7Ja

The tricuspid valve has gone from the “forgotten valve” to the most rapidly evolving frontier in structural heart disease. Excited to discuss “TTVR: Where Does It StandToday?” at CRT 2026 📍 Tricuspid Valve: New Frontiers session
🕣 Saturday 8:30 AM | International Ballroom East If you’re at CRT, join the Tricuspid Valve: New Frontiers session.

@jamiemccabeMD Great result!

LaPlace to the rescue! Unfortunate patient with torrential TR from bi-leaflet flail of the tricuspid valve. No commercial options but wonderfully (and simply!) treated with the LaPlace Transcatheter tricuspid valve via compassionate use pathway at Beth Israel Deaconess.

Finally @CMSGov re-opened much awaited #TAVR NCD. Public comment period ends Jan 14th. We must share our views. cms.gov/medicare-cover… Hopefully @SCAI @ACCinTouch will also represent member’s views. @kashishgoelmd @PaulMahoneyMD @drrahulpsharma @jtsaxon @djc795 @willsuh76 @SachinGoelMD @PedroMDMSc @PinakShahMD @DrTomWaggoner @aakriti_15 @kalazizimd @tavrkapadia @RonnieRamadan

Call it pushing boundaries, advancing medicine, or answering patient needs — early clinical trial access moves patient care forward. In the last two weeks alone, we (Vanderbilt) were able to help two patients who had no other options. Case #1: Patient with carcinoid disease with no septal leaflet to anchor for commercial Evoque TTVR or TriClip --> successfully treated with LAPLACE TTVR. Excellent result with no residual TR and the patient feeling great on day 1! Case #2: Patient with marked RV dilation and a large annulus precluding commercial Evoque or TriClip —> successfully treated with 60 mm TRISOL TTVR with an excellent result; next-day echo already showing RV remodeling with preserved RV function. @vumcvalve @VUMCDiscoveries

🌟 Ending strong! #SCAIFellows test out the latest VR technology and receive final pearls from faculty on the fellowship-to-practice journey. Comment your top tips for new interventional cardiologists. @AndrewMorseMD @PaulMahoneyMD @kashishgoelmd

Thrilled to share my new editorial just published in JACC: Cardiovascular Interventions on the increasingly important intersection of tricuspid regurgitation (TR) and cardiac implantable electronic device (CIED) leads. Key messages from the piece: ✅ Aim for the best possible TR reduction – ideally ≤1+. Accepting moderate (2+) residual TR as “good enough” is no longer acceptable in most patients. ✅ Lead management must be proactive and individualized ✅ Success requires a true multidisciplinary heart team – imaging, electrophysiology, interventional cardiology, and CT surgery Proud to share my viewpoint and grateful to the editors for the opportunity to highlight why we need to raise the bar for these complex patients. Full editorial (open access for next 50 days) here: #sec1" target="_blank" rel="nofollow noopener">sciencedirect.com/science/articl… @VUMChealth @VUMCDiscoveries @vumcvalve @JACCJournals @SCAI

@JoaoLCavalcante @hahn_rt @sarano_maurice @Miho_Fukui_ @psorajja @MHIF_Heart @drmaisano @PhilippLurz @FabienPraz @bapat_savrtavr @PatrizioLancel2 Really nice manuscript that moves the field forward. Hopefully, we can start applying this in clinical settings.

Redefining TR thresholds based on direct and objective measurements of right-sided remodeling, congestion and end-organ damage. Only then we can change the adage that "patients present too late..." lnkd.in/g5pqCdCv Actionable findings which can be implemented (1/4)

If you're interested in getting involved with SCAI, please apply to be on a committee!

@jaygirimd @usnews Seeing and hearing this a lot for the TVT star ratings as well. Hospitals are doing BAV rather than TAVR - risk aversion probably leading to harm

Evidence for risk aversion by TAVR teams that receive poor @usnews ratings. The latest life saving therapy limited due to public reports that have not been held to an evidentiary standard. Reports claim to support “transparency”, but good intentions don’t make sound policy.

What an incredible week that truly reflects our growth as a true destination center for percutaneous valve therapies!! Live Navitor case, MitraClip 101 faculty, & in between it all, our team tackled some truly advanced cases including first ICE-only Evoque TTVR, bioprosthetic MV vegetation removal with LA–LV fistula closure and a combined BATMAN, septal ablation → mitral ViV → tricuspid ViV in a shock patient (discharged home after a few days). Weeks like this underscore the strength of our program, the talent of our team, and our relentless commitment to advancing structural heart care. Proud of what we’re building — and excited for what’s ahead. @colinbarkerMD @VUMCDiscoveries